Thilo Schroeder, Ph.D.
President and Chief Executive Officer, Tyra Biosciences, Inc.
Start date not published.
Record provenance
- Alpha ID
- alpha:person:thilo-schroeder-ph-d
- Record version
- vpublic-0:d751713988987e9331980363e24189ce, published Sep 2, 2026
- Newest evidence
- Apr 21, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- Published claims
- 20 3 distinct sources
- Evidence records
- 9 0 pinned
- Source conflicts
- 0 None open
- Current role
- President and Chief Executive OfficerStart date not published
- Board seats
- 2Tyra Biosciences, Inc., Revolution Medicines, Inc.
- Committee seats
- 0None published
Governance snapshot
Inspect sourcesBoard oversight, responsibilities and disclosed experience. Each detail comes from this record’s published evidence.
Board service
Tyra Biosciences, Inc.
Current in the published record
Source disclosure: Apr 17, 2026. Status after that disclosure has not been established by this summary.
2026 to present; Current · dates not published
Appointment and supporting claimsRevolution Medicines, Inc.
Current in the published record
Source disclosure: Apr 29, 2025. Status after that disclosure has not been established by this summary.
2018 to present
Appointment and supporting claimsCommittee responsibilities
Committee memberships have not been published. This does not mean the person has no committee responsibilities.
How to read this record
Built from 3 distinct sources and 9 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
Public-role record. Alpha publishes facts about this person's role at an organization in the public Registry, drawn from regulatory filings and company statements, and nothing about private life. Any person or agent may read it. The subject can correct, dispute, or object. How this works
DIRECTOR APPOINTED
Thilo Schroeder, Ph.D. seat on Tyra Biosciences, Inc., effective 2026-04-17.
Board service
EvidenceSeats held as a director, as published in the cited sources.
Tyra Biosciences, Inc. CurrentDirector, 2026 to present. President, Chief Executive Officer and Director, Current · dates not publishedOpen recordRevolution Medicines, Inc. CurrentDirector, 2018 to presentOpen recordSupporting appointment claims (8)
Committee experience
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Work experience
Evidence- Current · dates not publishedPresident and Chief Executive OfficerTyra Biosciences, Inc.E4
Education, credentials, and certifications
EvidenceNo education, credentials, or certifications are published in this record.
No published claims
No education, credentials, or certifications are published in this record.
AI, cyber, and technology accountability
EvidenceAuthority to act
Evidence and agent registryWho may act on this authority. An agent about to transact, or one presenting itself as acting under this authority, checks these Claims first.
Compensation and holdings
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Conflicts and accountability
EvidenceOther published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Only permissioned public claims and evidence are included.Only permissioned public claims and evidence are included.
- Absence of a claim is not evidence that the underlying fact is false.Absence of a claim is not evidence that the underlying fact is false.
- Public retrieval does not grant model-training or redistribution rights.Public retrieval does not grant model-training or redistribution rights.
- Private relationships and Council activity are excluded.Private relationships and Council activity are excluded.
Linked records
Same claim, both recordsEach relationship is one Claim rendered on every record it connects.
- Tyra Biosciences, Inc.Director, 2026 to present; President, Chief Executive Officer and Director, Current · dates not published; President and Chief Executive Officer, Current · dates not publishedperson:thilo-schroeder-ph-d:role:1, person:thilo-schroeder-ph-d:role:4 +1
- Revolution Medicines, Inc.Director, 2018 to presentperson:thilo-schroeder-ph-d:role:2
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- EvidencecorroboratedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Subject and corrections
Public-role doctrineThis record exists because the subject holds a public role. The subject can claim the profile, correct, dispute, or object. Subject statements appear as their own assertion state and never overwrite the evidence.
- Basis
- Public role at an organization in the published Registry
- Sources
- 9 evidence records cited. 0 with redistribution rights.
- Never published
- Home address, family, personal contacts, health, and history unrelated to the public role
- Profile claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
If the subject claims the profile, their statements appear as their own assertion state, subject attested. They never overwrite the evidence.
Evidence
Authority and rights- E1SEC EDGAR. sec filing. Published Apr 21, 2026. Retrieved May 5, 2026. Cited by 2 Claims.
- E2SEC EDGAR. sec filing. Published Apr 17, 2026. Retrieved May 5, 2026. Cited by 5 Claims.
- E3sec proxy. Published Apr 17, 2026. Retrieved Sep 2, 2026. Cited by 1 Claim.
- E4sec def 14a. Published Apr 17, 2026. Retrieved Sep 14, 2026. Cited by 3 Claims.
- E5SEC EDGAR. sec filing. Published Apr 29, 2025. Retrieved Apr 30, 2026. Cited by 7 Claims.
- E6SEC EDGAR. sec filing. Published Apr 29, 2025. Retrieved May 3, 2026. Cited by 4 Claims.
- E7sec proxy. Published Apr 29, 2025. Retrieved Apr 30, 2026. Cited by 1 Claim.
- E8public source. Cited by 1 Claim.
- E9public source. Cited by 1 Claim.
What changed in version public-0:d751713988987e9331980363e24189ce
vpublic-0:d751713988987e9331980363e24189ce published Sep 2, 2026- Thilo Schroeder, Ph.D. seat on Tyra Biosciences, Inc., effective 2026-04-17.
- Thilo Schroeder, Ph.D. seat on Revolution Medicines, Inc., effective 2018-01-01.